Survival Benefits From Metformin Use in Pancreatic Cancer: A Systemic Review and Meta-analysis

Pancreas. 2018 Mar;47(3):e11-e14. doi: 10.1097/MPA.0000000000001000.

Authors

Kamonkiat Wirunsawanya¹, Veeravich Jaruvongvanich, Sikarin Upala

Affiliation

¹ Department of Internal Medicine, University of Hawaii, Honolulu, HI; Department of Medicine, Rangsit University, Bangkok, Thailand; Department of Internal Medicine, University of Hawaii, Honolulu, HI; Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand sikarin_u@hotmail.com.

PMID: 29424813
DOI: 10.1097/MPA.0000000000001000

No abstract available

Publication types

Letter
Meta-Analysis
Systematic Review

MeSH terms

Female
Humans
Hypoglycemic Agents / therapeutic use
Male
Metformin* / therapeutic use
Outcome Assessment, Health Care* / methods
Outcome Assessment, Health Care* / statistics & numerical data
Pancreatic Neoplasms* / drug therapy
Survival Analysis

Substances

Hypoglycemic Agents
Metformin